Aytu BioPharma (NASDAQ:AYTU) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Aytu BioPharma (NASDAQ:AYTU) from a hold rating to a strong sell rating in a research report released on Wednesday morning,Zacks.com reports.

A number of other research firms have also recently weighed in on AYTU. Ascendiant Capital Markets upped their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Aytu BioPharma has a consensus rating of “Hold” and an average price target of $10.75.

Aytu BioPharma Trading Down 0.5%

NASDAQ AYTU opened at $2.15 on Wednesday. The company’s fifty day simple moving average is $2.20 and its 200-day simple moving average is $2.43. Aytu BioPharma has a 52 week low of $1.65 and a 52 week high of $3.07. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The stock has a market cap of $23.07 million, a P/E ratio of -0.47 and a beta of 0.24.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.09). The firm had revenue of $12.41 million during the quarter, compared to analysts’ expectations of $12.05 million. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. Equities research analysts predict that Aytu BioPharma will post -0.73 EPS for the current fiscal year.

Institutional Trading of Aytu BioPharma

A number of hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in Aytu BioPharma during the 4th quarter valued at $67,000. Diadema Partners LP grew its holdings in Aytu BioPharma by 12.1% during the 4th quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock worth $795,000 after acquiring an additional 33,118 shares in the last quarter. Persistent Asset Partners Ltd grew its holdings in Aytu BioPharma by 27.2% during the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after acquiring an additional 16,963 shares in the last quarter. Rothschild Wealth LLC bought a new stake in shares of Aytu BioPharma in the 4th quarter worth about $52,000. Finally, DRW Securities LLC bought a new stake in shares of Aytu BioPharma in the 4th quarter worth about $76,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.